Mylan reports market availability of first generic Vivelle-DOT for vasomotor symptoms & vulvar and vaginal atrophy
M2 - Tue Dec 23, 5:22AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Tuesday that it has unveiled its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (twice weekly) in the market.
MYL: 56.97 (+0.39), NVS: 93.91 (+0.66)
Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:51PM CST
Actavis' (ACT) antibiotic, Xydalba, which is already marketed in the U.S. under the trade name Dalvance, is a step closer to EU approval.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Hold On To Teva!
Investing Tricks - at Seeking Alpha - Mon Dec 22, 2:09PM CST
MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66)
Mylan Launches First Generic Version of Vivelle-DOT®
PR Newswire - Mon Dec 22, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), which is the generic version of Novartis' Vivelle-DOT®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis.(1)
MYL: 56.97 (+0.39), NVS: 93.91 (+0.66)
5 Health Care Stocks John Paulson Is Buying Ahead of 2015
at The Street - Mon Dec 22, 6:00AM CST
Here's a closer look at five stocks Paulson & Co. bought in the most recently reported quarter.
MNK: 97.84 (-0.29), HCA: 74.89 (-0.11), COV: 103.35 (+0.57), MYL: 56.97 (+0.39), ABBV: 66.21 (+1.86)
Mylan Set to Possibly Pullback After Yesterday's Rally of 1.20%
Comtex SmarTrend(R) - Fri Dec 19, 3:45PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $56.56 to a high of $57.83. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $56.85 on volume of 7.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 56.97 (+0.39)
After Yesterday's Rally of 1.20% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Dec 19, 3:45PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $56.56 to a high of $57.83. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $56.85 on volume of 7.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 56.97 (+0.39)
Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 6:07PM CST
Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), MYL: 56.97 (+0.39)
Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference
PR Newswire - Wed Dec 17, 8:00AM CST
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 33rd Annual Healthcare Conference on Tuesday Jan. 13, 2015, in San Francisco.
JPM: 62.48 (unch), MYL: 56.97 (+0.39)
Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:20PM CST
Actavis plc (ACT) announced its decision to file an emergency appeal for an immediate overturn of the lower court ruling that will require the company to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Mylan (MYL) Crosses Pivot Point Resistance at $54.18
Comtex SmarTrend(R) - Mon Dec 15, 9:34AM CST
Mylan (NASDAQ:MYL) has opened bullishly above the pivot of $53.72 today and has reached the first level of resistance at $54.18. Investors may be interested in a cross of the next upside pivot targets of $55.03 and $56.34.
MYL: 56.97 (+0.39)
Teva's (TEVA) 2015 Guidance Hit By Generics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 4:20PM CST
Teva Pharmaceutical Industries Ltd (TEVA) provided a narrower-than-expected outlook for 2015.
BIIB: 340.89 (+5.13), MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:20PM CST
Actavis plc (ACT) may face an injunction under which the company will have to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Teva Upgraded On Strength Of Copaxone MS Drug
at Investor's Business Daily - Fri Dec 12, 9:38AM CST
Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning,...
MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66)
Mylan Among First to Launch Generic Celebrex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 3:22PM CST
Mylan Inc. announced that it has launched the generic version of Pfizer's Celebrex.
ACT: 254.20 (-1.68), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33)
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)
Mylan Launches Generic Robaxin® Injection
PR Newswire - Thu Dec 11, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Methocarbamol Injection, which is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Mylan's immediate shipment of this product supports the growth of the company's portfolio of more than 100 injectable products in the U.S.
MYL: 56.97 (+0.39)
Mylan Launches First Generic Version of Orapred ODT®
PR Newswire - Thu Dec 11, 6:00AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg, and was awarded 180 days of generic drug marketing exclusivity. This product is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions.
MYL: 56.97 (+0.39)
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)
Mylan Launches One of First Available Generic Versions of Celebrex® Capsules
PR Newswire - Wed Dec 10, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.(1)
MYL: 56.97 (+0.39)